08:00 , Jan 15, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Peroxisome proliferator activated receptor (PPAR) α; PPARγ coactivator 1-α (PPARGC1A, PGC-1a)

Renal INDICATION: Renal disease Studies in mice and patient samples suggest stimulating fatty acid oxidation (FAO) could help treat kidney fibrosis. In samples from patients with chronic kidney disease, mRNA levels of key FAO enzymes and the...
08:00 , Jan 12, 2015 |  BioCentury  |  Emerging Company Profile

Targeting transcription regulators

The founders of Inventiva S.A.S. are using a platform from predecessor company Laboratoires Fournier S.A. to discover small molecules that target epigenetic enzymes, transcription factors and nuclear receptors for oncology, fibrosis and autoimmune disease. The...
08:00 , Nov 24, 2014 |  BioCentury  |  Product Development

LDL Does IMPROVE IT

The long-awaited results from the IMPROVE-IT cardiovascular outcomes trial have been hailed as opening the gates for next-generation cholesterol drugs to gain approval on the basis of LDL reductions alone. That may be true. But...
02:08 , Oct 14, 2014 |  BC Extra  |  Financial News

Anatara raises A$7M in Australian IPO

Anatara Lifesciences Ltd. (ASX:ANR), which is seeking partners for human development of its non-antibiotic therapy to treat and prevent diarrhea, raised A$7 million ($6.1 million) through the sale of 14 million shares at A$0.50 in...
07:00 , Apr 14, 2014 |  BioCentury  |  Product Development

Family resemblance

The early Phase III data appear similar for competing anti-PCSK9 mAbs from Amgen Inc. on one end and partners Regeneron Pharmaceuticals Inc. and Sanofi on the other. But starting mid-year, additional data in the populations...
08:00 , Feb 3, 2014 |  BioCentury  |  Regulation

Lipid advice in Europe

A lack of clarity about requirements for cardiovascular safety and outcomes data in updated EMA guidance means companies developing lipid-modulating therapies will need to seek individual advice from the European regulator as early as possible...
08:00 , Feb 3, 2014 |  BioCentury  |  Finance

Quick payday on single cell sale

A quick turnaround from first financing to takeout netted investors in DVS Sciences Inc. an impressive return in a short time. On Jan. 29, Fluidigm Corp. (NASDAQ:FLDM) announced plans to acquire fellow microfluidics company DVS for...
08:00 , Nov 4, 2013 |  BC Week In Review  |  Clinical News

Antara fenofibrate regulatory update

Lupin said FDA approved an sNDA for 30 and 90 mg strengths of Antara fenofibrate as an adjunct treatment for hypercholesterolemia, mixed dyslipidemia and hypertriglyceridemia in combination with diet. Lupin, which already markets 43 and...
07:00 , Oct 28, 2013 |  BioCentury  |  Finance

Paying the iron price

A group of VCs and Novartis AG (NYSE:NVS; SIX:NOVN) are betting that Sideris Pharmaceuticals Inc.'s iron chelator program can better the pharma's iron overload drug Exjade deferasirox, as well as a compound from Shire plc...
07:00 , Jul 29, 2013 |  BioCentury  |  Finance

Green shoots in autumn

Last week's string of IPOs may be the last big burst of activity before the dog days of August. But two biobankers told BioCentury they expect a ramp-up in September and a flurry of IPO...